300347 泰格医药
交易中 01-15 11:14:30
资讯
新帖
简况
泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%
证券之星 · 01-06
泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%
市值蒸发超千亿，深证100“踢群”泰格医药
视频滚动新闻 · 2025-12-18
市值蒸发超千亿，深证100“踢群”泰格医药
主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？
华夏时报网 · 2025-12-17
主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？
重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散
深圳商报·读创 · 2025-12-14
重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散
泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%
证券之星 · 2025-12-11
泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%
泰格医药（300347）新增【AIGC】概念
证券之星 · 2025-12-04
泰格医药（300347）新增【AIGC】概念
兴证全球基金减持泰格医药(03347)21.68万股 每股作价约37.7港元
智通财经 · 2025-12-04
兴证全球基金减持泰格医药(03347)21.68万股 每股作价约37.7港元
杭州泰格医药科技股份有限公司发布2025年11月证券变动月报
中金财经 · 2025-12-03
杭州泰格医药科技股份有限公司发布2025年11月证券变动月报
港股生物医药板块持续走低，泰格医药、君实生物跌超3%
每日经济新闻 · 2025-12-02
港股生物医药板块持续走低，泰格医药、君实生物跌超3%
小摩减持泰格医药(03347)约83.12万股 每股均价约39.82港元
智通财经 · 2025-12-01
小摩减持泰格医药(03347)约83.12万股 每股均价约39.82港元
小摩增持泰格医药(03347)约50.15万股 每股作价约38.95港元
智通财经网 · 2025-11-27
小摩增持泰格医药(03347)约50.15万股 每股作价约38.95港元
港股异动 | 泰格医药(03347)涨超4% 公司Q3单季度收入明显改善 SMO业务新签订单保持双位数增长
智通财经 · 2025-11-10
港股异动 | 泰格医药(03347)涨超4% 公司Q3单季度收入明显改善 SMO业务新签订单保持双位数增长
泰格医药新注册《泰格集团项目预算管理软件V1.0》项目的软件著作权
证券之星 · 2025-11-06
泰格医药新注册《泰格集团项目预算管理软件V1.0》项目的软件著作权
里昂：维持泰格医药(03347)跑赢大市评级 第三季度温和复苏
智通财经网 · 2025-10-30
里昂：维持泰格医药(03347)跑赢大市评级 第三季度温和复苏
泰格医药（300347）2025年三季报简析：净利润同比增长25.45%，公司应收账款体量较大
中金财经 · 2025-10-30
泰格医药（300347）2025年三季报简析：净利润同比增长25.45%，公司应收账款体量较大
泰格医药(03347)发布前三季度业绩 归母净利润10.2亿元 同比增加25.45%
智通财经 · 2025-10-28
泰格医药(03347)发布前三季度业绩 归母净利润10.2亿元 同比增加25.45%
易方达基金减持泰格医药(03347)42.98万股 每股作价约42.78港元
智通财经 · 2025-10-24
易方达基金减持泰格医药(03347)42.98万股 每股作价约42.78港元
易方达基金管理有限公司增持泰格医药(03347)57.31万股 每股作价约42.09港元
智通财经 · 2025-10-16
易方达基金管理有限公司增持泰格医药(03347)57.31万股 每股作价约42.09港元
高盛：首次覆盖泰格医药(03347)H股予“买入”评级 目标价62.1港元
智通财经 · 2025-10-14
高盛：首次覆盖泰格医药(03347)H股予“买入”评级 目标价62.1港元
股市必读：泰格医药（300347）10月10日董秘有最新回复
证券之星 · 2025-10-13
股市必读：泰格医药（300347）10月10日董秘有最新回复
加载更多
公司概况
公司名称：
杭州泰格医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2012-08-17
主营业务：
杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。
发行价格：
37.88
{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":62.99,"timestamp":1768446870000,"preClose":63,"halted":0,"volume":6328550,"delay":0,"changeRate":-0.0002,"floatShares":566000000,"shares":861000000,"eps":0.711,"marketStatus":"交易中","change":-0.01,"latestTime":"01-15 11:14:30","open":62.58,"high":64.48,"low":61.84,"amount":400000000,"amplitude":0.0419,"askPrice":63,"askSize":75,"bidPrice":62.97,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.711,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1768447800000},"marketStatusCode":2,"adr":0,"adjPreClose":63,"symbolType":"stock","openAndCloseTimeList":[[1768440600000,1768447800000],[1768453200000,1768460400000]],"highLimit":69.3,"lowLimit":56.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":861026050,"isCdr":false,"pbRate":2.56,"roa":"--","peRate":88.59353,"roe":"4.89%","epsLYR":0.47,"committee":-0.574468,"marketValue":54236000000,"turnoverRate":0.0112,"status":1,"hkstockBrief":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":53.95,"timestamp":1768446854838,"preClose":53,"halted":0,"volume":635200,"delay":0,"premium":"-23.46"},"floatMarketCap":35666000000},"requestUrl":"/m/hq/s/300347","defaultTab":"news","newsList":[{"id":"2601136618","title":"泰格医药（300347）披露证券变动月报表，1月6日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601136618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601136618?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:18","pubTimestamp":1767709099,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，泰格医药报收于58.98元，较前一交易日下跌0.32%，最新总市值为507.83亿元。A股和H股的法定股份数目分别为737,901,250股和123,124,800股，面值均为人民币1元。已发行股份总数无变动，其中A股已发行股份为732,017,470股，库存股为5,883,780股，H股已发行股份为123,124,800股，无库存股。公告显示，公司于2024年至2025年期间多次购回A股并持有为库存股份，并于2025年5月注销部分库存股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","LU1146622755.USD","LU1820825898.SGD","BK1576","BK1141","BK1583","BK0174","BK0028","BK0077","BK0216","03347","300347"],"gpt_icon":0},{"id":"2592908047","title":"市值蒸发超千亿，深证100“踢群”泰格医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908047","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592908047?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:56","pubTimestamp":1766058960,"startTime":"0","endTime":"0","summary":"12月15日，泰格医药被调出深证100成分股，结束6年指数生涯。尽管其2025年前三季度净利润同比涨20.88%，但股价逆市下跌6.7%，市值从1700亿高点跌至430亿左右，收入规模、营收增速、ROE等指标也逊于深证100平均水平。资金方面，高管持续减持，公募基金持仓大降。不过，部分机构仍唱多。此外，泰格医药投资布局广，但近期业绩承压、流动性告急，开始退出项目回笼资金，虽净利润反转，但市场并不买账，重拾信心或取决于主业盈利能力修复。(AI生成)\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-12-18/doc-inhcfrcf8410958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","399330","BK0028","300347","161227","BK0216","BK1576","BK1583","BK1141","LU1820825898.SGD","BK0174","LU1146622755.USD","BK0077"],"gpt_icon":0},{"id":"2592291364","title":"主业疲软、投资“撑场”：CRO龙头泰格医药指数“光环”褪色，千亿市值因何蒸发？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592291364","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592291364?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:45","pubTimestamp":1765979156,"startTime":"0","endTime":"0","summary":"国内临床CRO龙头企业泰格医药（300347.SZ）于12月15日起正式被调出深证100成份股，结束了自2019年12月纳入以来长达六年的指数生涯。此次调整正值CRO行业因“猴荒”再现迎来普涨行情，板块内多数企业股价上行。然而，泰格医药走势却与行业背离，成为板块中唯一的“失意者”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512173594505571.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512173594505571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0077","BK1141","LU1820825898.SGD","BK0028","LU1146622755.USD","03347","300347","BK1576","BK0174","BK0216","BK1583"],"gpt_icon":0},{"id":"2591657113","title":"重要指数样本股调整，泰格医药黯然离场，1350亿市值已烟消云散","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657113","media":"深圳商报·读创","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657113?lang=zh_cn&edition=full","pubTime":"2025-12-14 15:06","pubTimestamp":1765696006,"startTime":"0","endTime":"0","summary":"国内临床CRO龙头泰格医药(300347)，即将被调出深证100指数样本股，其市值较高点已蒸发1350亿元。日前，深圳证券交易所及深圳证券信息有限公司发布公告，根据指数编制规则，将对深证成指、创业板指、深证100、创业板50等深市指数实施样本定期调整。本次调整将于12月15日正式实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512143590930292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","03347","BK1583","BK0028","LU1820825898.SGD","BK0216","BK0077","BK1141","LU1146622755.USD","300347","BK0174"],"gpt_icon":0},{"id":"2590591678","title":"泰格医药（300347）披露第五届董事会审计委员会成员及召集人，12月11日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590591678","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590591678?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:44","pubTimestamp":1765446288,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，泰格医药报收于49.19元，较前一交易日下跌1.4%，最新总市值为423.54亿元。公司近日发布公告称，杭州泰格医药科技股份有限公司于2025年12月9日召开第五届董事会第二十次会议，审议通过《关于确认公司第五届董事会审计委员会成员及召集人的议案》。公告显示，第五届董事会审计委员会由廖启宇先生、袁华刚先生、刘毓文女士组成，召集人为廖启宇先生，任期自董事会审议通过之日起至第五届董事会届满之日止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100028560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1820825898.SGD","BK1576","300347","BK0174","BK0077","BK0028","BK1141","LU1146622755.USD","BK0216","BK1583","03347"],"gpt_icon":0},{"id":"2588881150","title":"泰格医药（300347）新增【AIGC】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588881150?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:30","pubTimestamp":1764851432,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，12月4日泰格医药新增概念。该公司关联的其它概念板块还包括：AI医疗概念、CXO概念、创新药。泰格医药主营业务：临床试验技术服务和临床试验相关服务及实验室服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK1583","BK0077","LU1146622755.USD","BK0028","BK1576","300347","03347","BK1141","BK0216","LU1820825898.SGD"],"gpt_icon":1},{"id":"2588885266","title":"兴证全球基金减持泰格医药(03347)21.68万股 每股作价约37.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885266","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588885266?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:15","pubTimestamp":1764846940,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月3日，兴证全球基金管理有限公司减持泰格医药(03347)21.68万股，每股作价37.7041港元，总金额约为817.42万港元。减持后最新持股数目为603.35万股，最新持股比例为4.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","03347","BK0174","BK0028","BK0216","300347","LU1820825898.SGD","BK1141","BK1576","BK1583","BK0077"],"gpt_icon":0},{"id":"2588408017","title":"杭州泰格医药科技股份有限公司发布2025年11月证券变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2588408017","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588408017?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:20","pubTimestamp":1764757214,"startTime":"0","endTime":"0","summary":"中访网数据 杭州泰格医药科技股份有限公司于2025年12月3日向香港交易及结算所有限公司提交了截至2025年11月30日的证券变动月报表。A股法定及已发行股本总额均为737,901,250股，每股面值人民币1元；H股法定及已发行股本总额均为123,124,800股，每股面值人民币1元。截至报告期末，公司法定股本总额为人民币861,026,050元。其中，公司已于2025年5月29日注销了3,922,520股库存股份。本次月报期内，公司已发行股份总数及库存股份数量均未发生变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31842009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0077","BK0216","300347","03347","BK1576","BK0028","LU1820825898.SGD","LU1146622755.USD","BK0174","BK1583","161027","BK1141"],"gpt_icon":0},{"id":"2588608692","title":"港股生物医药板块持续走低，泰格医药、君实生物跌超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588608692","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588608692?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:49","pubTimestamp":1764647365,"startTime":"0","endTime":"0","summary":"港股生物医药板块持续走低，泰格医药、君实生物跌超3%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023580206556.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580206556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","03347","399441","BK1141","BK1576","LU1146622755.USD","LU1820825898.SGD","BK0077","BK0028","BK1583","300347","688180","BK0216","BK1161","BK0239","01877","BK0174","161726"],"gpt_icon":0},{"id":"2588727114","title":"小摩减持泰格医药(03347)约83.12万股 每股均价约39.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727114","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588727114?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:34","pubTimestamp":1764592469,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月25日，小摩减持泰格医药(03347)83.1247万股，每股均价39.8240港元，总金额约为3310.36万港元。减持后最新持股数目约为950.93万股，最新持股比例为7.72%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0882574139.USD","LU1670628061.USD","LU0868494708.USD","LU2023250330.USD","LU0251132253.USD","LU1244550577.SGD","IE00BDCRKT87.USD","LU0006306889.USD","LU0820562030.AUD","IE00BFXG1179.USD","LU0211326839.USD","03347","LU2381873111.SGD","LU2106854487.HKD","BK4533","LU1914381329.SGD","LU0170899867.USD","BK4516","LU0048584097.USD","IE0034235188.USD","LU0106831901.USD","LU0640476718.USD","LU1145028129.USD","LU0496365809.HKD","LU0265550359.USD","LU1894683348.USD","LU0345770993.USD","LU0683600562.USD","LU0942090050.USD","LU2236285917.USD","LU0106261372.USD","LU2462157665.USD","LU0320765646.SGD","SG9999002232.USD","LU2264538146.SGD","IE00BHPRN162.USD","IE0034235303.USD","IE00B775SV38.USD","BK4585","IE00BN8TJ469.HKD","LU1244550494.USD","BK4534","BK4504","LU1668664300.SGD","LU1496350502.SGD","IE00B1BXHZ80.USD","300347","LU0417517546.SGD","LU0820561818.USD","IE00BJLML261.HKD"],"gpt_icon":0},{"id":"2586270244","title":"小摩增持泰格医药(03347)约50.15万股 每股作价约38.95港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586270244","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586270244?lang=zh_cn&edition=full","pubTime":"2025-11-27 18:45","pubTimestamp":1764240301,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，11月24日，小摩增持泰格医药(03347)50.1547万股，每股作价38.9488港元，总金额约为1953.47万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251127/20251127184516_45694.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251127/20251127184516_45694.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BKDWB100.SGD","BK0174","IE00BZ1G4Q59.USD","LU2456880835.USD","BK4566","LU2462157665.USD","LU2552382215.SGD","IE00BJTD4N35.SGD","IE00BFXG1179.USD","LU0211328371.USD","LU2756315318.SGD","BK0077","LU0149725797.USD","LU1548497426.USD","LU0868494708.USD","LU1496350171.SGD","IE00BLSP4452.SGD","LU2430703251.USD","03347","LU0203347892.USD","LU1244550494.USD","LU1366192091.USD","BK0216","LU1551013425.SGD","LU0048584097.USD","BK1576","LU2054465674.USD","IE00BBT3K403.USD","LU0976567544.SGD","LU1261432733.SGD","LU2237443895.HKD","LU1146622755.USD","LU0170899867.USD","LU2106854487.HKD","LU0943347566.SGD","LU1988902786.USD","IE00BJLML261.HKD","LU1670627923.USD","LU2430703178.SGD","LU0251132253.USD","LU0211326755.USD","LU2236285917.USD","LU0640476718.USD","LU0006306889.USD","300347","LU2552382132.HKD","LU0238689110.USD","LU2023250504.SGD","LU0106831901.USD","LU2023250330.USD"],"gpt_icon":0},{"id":"2582781055","title":"港股异动 | 泰格医药(03347)涨超4% 公司Q3单季度收入明显改善 SMO业务新签订单保持双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2582781055","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582781055?lang=zh_cn&edition=full","pubTime":"2025-11-10 10:13","pubTimestamp":1762740792,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，泰格医药涨超4%，截至发稿，涨3.15%，报43.9港元，成交额2072.05万港元。消息面上，近日，泰格医药发布2025年第三季度报告，该集团前三季度取得营业收入50.26亿元，同比减少0.82%；归母净利润10.2亿元，同比增加25.45%。华创证券指出，公司2025Q3单季度收入同比增长3.86%，较H1的同比下降3.21%明显改善。SMO业务新签订单保持双位数增长，业务韧性较强，发展态势可期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0174","BK1141","BK1583","BK0216","BK0028","300347","LU1146622755.USD","BK1576","03347","LU1820825898.SGD","BK0077"],"gpt_icon":0},{"id":"2581770724","title":"泰格医药新注册《泰格集团项目预算管理软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2581770724","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581770724?lang=zh_cn&edition=full","pubTime":"2025-11-06 01:52","pubTimestamp":1762365136,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药新注册了《泰格集团项目预算管理软件V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权14个，较去年同期减少了12.5%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了1.27亿元，同比增1.85%。通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了57家企业，参与招投标项目50次；财产线索方面有商标信息75条，专利信息17条，著作权信息164条；此外企业还拥有行政许可45个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600001223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1820825898.SGD","BK1583","03347","BK0216","BK1576","LU1146622755.USD","BK0077","BK0174","300347","BK0028","BK1141"],"gpt_icon":0},{"id":"2579060118","title":"里昂：维持泰格医药(03347)跑赢大市评级 第三季度温和复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2579060118","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579060118?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:25","pubTimestamp":1761816318,"startTime":"0","endTime":"0","summary":"目标价从58.9港元下调至52.1港元，仍维持“跑赢大市”评级。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251030/20251030172842_29312.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251030/20251030172842_29312.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300347","03347"],"gpt_icon":0},{"id":"2579156276","title":"泰格医药（300347）2025年三季报简析：净利润同比增长25.45%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579156276","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579156276?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:06","pubTimestamp":1761782767,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泰格医药发布2025年三季报。截至本报告期末，公司营业总收入50.26亿元，同比下降0.82%，归母净利润10.2亿元，同比上升25.45%。按单季度数据看，第三季度营业总收入17.75亿元，同比上升3.86%，第三季度归母净利润6.37亿元，同比上升98.73%。本报告期泰格医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达352.26%。去年的净利率为6.78%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/30/20251030934813.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/30/20251030934813.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300347","03347"],"gpt_icon":0},{"id":"2578938099","title":"泰格医药(03347)发布前三季度业绩 归母净利润10.2亿元 同比增加25.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578938099","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578938099?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:38","pubTimestamp":1761640701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布2025年第三季度报告，该集团前三季度取得营业收入50.26亿元，同比减少0.82%;归母净利润10.2亿元，同比增加25.45%;每股基本收益1.19元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347"],"gpt_icon":0},{"id":"2577513663","title":"易方达基金减持泰格医药(03347)42.98万股 每股作价约42.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577513663","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577513663?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:37","pubTimestamp":1761305854,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月21日，易方达基金管理有限公司减持泰格医药(03347)42.98万股，每股作价42.779港元，总金额约为1838.64万港元。减持后最新持股数目为946.81万股，持股比例为7.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1141","BK0028","BK0077","BK0216","LU1820825898.SGD","BK0174","300347","BK1576","LU1146622755.USD","03347"],"gpt_icon":0},{"id":"2575710091","title":"易方达基金管理有限公司增持泰格医药(03347)57.31万股 每股作价约42.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710091","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575710091?lang=zh_cn&edition=full","pubTime":"2025-10-16 18:56","pubTimestamp":1760612162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月13日，易方达基金管理有限公司增持泰格医药(03347)57.31万股，每股作价42.0922港元，总金额约为2412.3万港元。增持后最新持股数目为1036.01万股，持股比例为8.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347","BK0028","BK0216","BK1576","BK1583","LU1820825898.SGD","BK1141","BK0174","LU1146622755.USD","BK0077"],"gpt_icon":0},{"id":"2575627266","title":"高盛：首次覆盖泰格医药(03347)H股予“买入”评级 目标价62.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575627266","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575627266?lang=zh_cn&edition=full","pubTime":"2025-10-14 14:25","pubTimestamp":1760423123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，将泰格医药A股评级由“中性”升至“买入”，目标价由62.1元人民币升至77.1元人民币，并首次覆盖泰格医药H股予“买入”评级，目标价62.1港元。该行将2026至27年每股盈利预测分别上调9%及13%，并预期2026至28年EBIT利润率将分别上升180、150及190个基点，基于减值损失降低、营运杠杆改善及成本管控强化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","03347"],"gpt_icon":0},{"id":"2575144835","title":"股市必读：泰格医药（300347）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575144835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575144835?lang=zh_cn&edition=full","pubTime":"2025-10-13 05:24","pubTimestamp":1760304260,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，泰格医药报收于55.62元，下跌2.27%，换手率1.95%，成交量11.04万手，成交额6.19亿元。董秘最新回复投资者： 请问公司是否与辉瑞或者礼来等公司存在业务合作？公司服务过3600余家全球客户，公司曾获得礼来“全球供应商奖”。当日关注点来自交易信息汇总：10月10日主力资金净流入114.97万元，显示主力对泰格医药股价短期走势持相对积极态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300001973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0028","BK1141","03347","BK0216","LU1820825898.SGD","BK1576","LU1146622755.USD","BK1583","300347","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768446874306,"stockEarnings":[{"period":"1week","weight":0.0448},{"period":"1month","weight":0.2781},{"period":"3month","weight":0.1562},{"period":"6month","weight":0.0766},{"period":"1year","weight":0.2523},{"period":"ytd","weight":0.1111}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2012-08-17","address":"浙江省杭州市滨江区西兴街道聚工路19号8幢20层2001-2010室","registeredCapital":"86102万元","survey":" 杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,300347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}